Bristol-Myers Squibb Co. (BMY)

Analysis of Income Taxes

Difficulty: Advanced

Income Tax Accounting Policy

The provision for income taxes includes income taxes paid or payable for the current year plus the change in deferred taxes during the year. Deferred taxes result from differences between the financial and tax basis of assets and liabilities and are adjusted for changes in tax rates and tax laws when changes are enacted. Valuation allowances are recognized to reduce deferred tax assets when it is more likely than not that a tax benefit will not be realized. The assessment of whether or not a valuation allowance is required often requires significant judgment including the long-range forecast of future taxable income and the evaluation of tax planning initiatives. Adjustments to the deferred tax valuation allowances are made to earnings in the period when such assessments are made.

Tax benefits are recognized from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities based on the technical merits of the position. The tax benefit recognized in the financial statements for a particular tax position is based on the largest benefit that is more likely than not to be realized upon settlement.

Source: Bristol-Myers Squibb Co., Annual Report

Top

Income Tax Expense (Benefit)

Bristol-Myers Squibb Co., income tax expense (benefit), continuing operations

USD $ in millions

12 months ended	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015	Dec 31, 2014	Dec 31, 2013
U.S.	2,782	1,144	337	334	375
Non-U.S.	364	468	456	560	427
Current	3,146	1,612	793	894	802
U.S.	1,063	(101)	(394)	(403)	(390)
Non-U.S.	(53)	(103)	47	(139)	(101)
Deferred	1,010	(204)	(347)	(542)	(491)
Provision for income taxes	4,156	1,408	446	352	311

Source: Based on data from Bristol-Myers Squibb Co. Annual Reports

Item	Description	The company
Current	The component of income tax expense for the period representing amounts of income taxes paid or payable (or refundable) for the period for all income tax obligations as determined by applying the provisions of relevant enacted tax laws to relevant amounts of taxable income (loss) from continuing operations.	Bristol-Myers Squibb Co.'s current increased from 2015 to 2016 and from 2016 to 2017.
Deferred	The component of income tax expense for the period representing the net change in the entity's deferred tax assets and liabilities pertaining to continuing operations.	Bristol-Myers Squibb Co.'s deferred increased from 2015 to 2016 and from 2016 to 2017.
Provision for income taxes	The sum of the current income tax expense (benefit) and the deferred income tax expense (benefit) pertaining to pretax income (loss) from continuing operations; income tax expense (benefit) may include interest and penalties on tax uncertainties based on the entity's accounting policy.	Bristol-Myers Squibb Co.'s provision for income taxes increased from 2015 to 2016 and from 2016 to 2017.

Top

Effective Income Tax Rate (EITR)

Bristol-Myers Squibb Co., effective income tax rate (EITR) reconciliation

	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015	Dec 31, 2014	Dec 31, 2013
U.S. statutory Federal income tax rate	35.00%	35.00%	35.00%	35.00%	35.00%
Deemed repatriation transition tax	50.90%	–%	–%	–%	–%
Deferred tax remeasurement	5.60%	–%	–%	–%	–%
Foreign tax effect of certain operations in Ireland, Puerto Rico and Switzerland	-10.90%	-7.50%	-25.80%	-21.40%	-21.40%
U.S. tax effect of capital losses	–%	–%	–%	-15.20%	–%
U.S. Federal valuation allowance release	–%	-0.50%	-4.00%	–%	-0.30%
U.S. Federal, state and foreign contingent tax matters	1.40%	1.50%	2.70%	9.60%	4.60%
U.S. Federal research based credits	-2.80%	-2.40%	-6.40%	-5.40%	-7.60%
Goodwill allocated to divestitures	0.10%	0.60%	1.20%	8.80%	–%
U.S. Branded Prescription Drug Fee	1.00%	0.90%	2.10%	3.50%	2.20%
Non-deductible R&D charges	5.20%	1.70%	17.80%	2.20%	–%
Puerto Rico excise tax	-2.60%	-2.20%	-2.70%	-1.20%	–%
Domestic manufacturing deduction	-1.50%	-2.10%	-0.80%	–%	–%
State and local taxes, net of valuation allowance	1.50%	0.40%	0.80%	0.80%	0.90%
Foreign and other	-1.90%	-1.60%	1.60%	-1.90%	-2.60%
Effective tax rate	81.00%	23.80%	21.50%	14.80%	10.80%

Source: Based on data from Bristol-Myers Squibb Co. Annual Reports

Item	Description	The company
Effective tax rate	A ratio calculated by dividing the reported amount of income tax expense attributable to continuing operations for the period by GAAP-basis pretax income from continuing operations.	Bristol-Myers Squibb Co.'s effective tax rate increased from 2015 to 2016 and from 2016 to 2017.

Top

Components of Deferred Tax Assets and Liabilities

Bristol-Myers Squibb Co., components of deferred tax assets and liabilities

USD $ in millions

	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015	Dec 31, 2014	Dec 31, 2013
Foreign net operating loss carryforwards	2,872	2,945	3,090	3,473	3,892
State net operating loss and credit carryforwards	143	114	324	337	377
U.S. Federal net operating loss and credit carryforwards	99	156	173	161	161
Deferred income	212	764	1,009	1,163	2,168
Milestone payments and license fees	386	534	560	440	483
Pension and postretirement benefits	131	358	462	467	120
Intercompany profit and other inventory items	651	1,241	607	531	495
Other foreign deferred tax assets	312	188	172	202	187
Share-based compensation	60	114	122	95	107
Internal transfer of intellectual property	–	629	635	247	223
Other	280	308	438	981	1,210
Deferred tax assets	5,146	7,351	7,592	8,097	9,423
Valuation allowance	(2,827)	(3,078)	(3,534)	(4,259)	(4,623)
Deferred tax assets net of valuation allowance	2,319	4,273	4,058	3,838	4,800
Depreciation	(11)	(125)	(105)	(128)	(148)
Acquired intangible assets	(216)	(344)	(338)	(390)	(2,567)
Goodwill and other	(527)	(855)	(802)	(832)	(780)
Deferred tax liabilities	(754)	(1,324)	(1,245)	(1,350)	(3,495)
Deferred tax assets (liabilities), net	1,565	2,949	2,813	2,488	1,305

Source: Based on data from Bristol-Myers Squibb Co. Annual Reports

Item	Description	The company
Deferred tax assets	The sum of the tax effects as of the balance sheet date of the amounts of all future tax deductions arising from temporary differences between tax basis and generally accepted accounting principles basis recognition of assets, liabilities, revenues and expenses, which can only be deducted for tax purposes when permitted under enacted tax laws (before the valuation allowance, if any, to reduce such sum amount to net realizable value). Includes any tax benefit realized in deferred tax assets for significant impacts of tax planning strategies.	Bristol-Myers Squibb Co.'s deferred tax assets declined from 2015 to 2016 and from 2016 to 2017.
Deferred tax assets net of valuation allowance	The aggregate tax effects as of the balance sheet date of all future tax deductions arising from temporary differences between tax basis and generally accepted accounting principles basis recognition of assets, liabilities, revenues and expenses, which can only be deducted for tax purposes when permitted under enacted tax laws; net of deducting the allocated valuation allowance, if any, to reduce such amount to net realizable value.	Bristol-Myers Squibb Co.'s deferred tax assets net of valuation allowance increased from 2015 to 2016 but then declined significantly from 2016 to 2017.
Deferred tax assets (liabilities), net	For entities that net deferred tax assets and tax liabilities, represents the unclassified net amount of deferred tax assets and liabilities as of the balance sheet date, which result from applying the applicable enacted tax rate to net temporary differences and carryforwards pertaining to assets or liabilities. A temporary difference is a difference between the tax basis of an asset or liability and its carrying amount in the financial statements prepared in accordance with generally accepted accounting principles that will reverse in ensuing periods.	Bristol-Myers Squibb Co.'s deferred tax assets (liabilities), net increased from 2015 to 2016 but then declined significantly from 2016 to 2017.

Top

Deferred Tax Assets and Liabilities, Classification

Bristol-Myers Squibb Co., deferred tax assets and liabilities, classification

USD $ in millions

	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015	Dec 31, 2014	Dec 31, 2013
Deferred income tax assets, current	–	–	–	1,644	1,826
Deferred income tax assets, non-current	1,610	2,996	2,844	915	508
Deferred income tax liabilities, current (included in income taxes payable)	–	–	–	11	956
Deferred income tax liabilities, non-current (included in income taxes payable)	45	47	31	60	73

Source: Based on data from Bristol-Myers Squibb Co. Annual Reports

Item	Description	The company
Deferred income tax assets, current	The current portion of the aggregate tax effects as of the balance sheet date of all future tax deductions arising from temporary differences between tax basis and generally accepted accounting principles basis recognition of assets, liabilities, revenues and expenses, which can only be deducted for tax purposes when permitted under enacted tax laws; after deducting the allocated valuation allowance, if any, to reduce such amount to net realizable value. Deferred tax liabilities and assets shall be classified as current or noncurrent based on the classification of the related asset or liability for financial reporting. A deferred tax liability or asset that is not related to an asset or liability for financial reporting, including deferred tax assets related to carryforwards, shall be classified according to the expected reversal date of the temporary difference. An unrecognized tax benefit that is directly related to a position taken in a tax year that results in a net operating loss carryforward should be presented as a reduction of the related deferred tax asset.
Deferred income tax assets, non-current	The noncurrent portion as of the balance sheet date of the aggregate carrying amount of all future tax deductions arising from temporary differences between tax basis and generally accepted accounting principles basis recognition of assets, liabilities, revenues and expenses, which can only be deducted for tax purposes when permitted under enacted tax laws; after the valuation allowance, if any, to reduce such amount to net realizable value. Deferred tax liabilities and assets shall be classified as current or noncurrent based on the classification of the related asset or liability for financial reporting. A deferred tax liability or asset that is not related to an asset or liability for financial reporting, including deferred tax assets related to carryforwards, shall be classified according to the expected reversal date of the temporary difference.	Bristol-Myers Squibb Co.'s deferred income tax assets, non-current increased from 2015 to 2016 but then declined significantly from 2016 to 2017.
Deferred income tax liabilities, current (included in income taxes payable)	Represents the current portion of deferred tax liabilities, which result from applying the applicable tax rate to net taxable temporary differences pertaining to each jurisdiction to which the entity is obligated to pay income tax. A current taxable temporary difference is a difference between the tax basis and the carrying amount of a current asset or liability in the financial statements prepared in accordance with generally accepted accounting principles. In a classified statement of financial position, an enterprise shall separate deferred tax liabilities and assets into a current amount and a noncurrent amount. Deferred tax liabilities and assets shall be classified as current or noncurrent based on the classification of the related asset or liability for financial reporting. A deferred tax liability or asset that is not related to an asset or liability for financial reporting, including deferred tax assets related to carryforwards, shall be classified according to the expected reversal date of the temporary difference.
Deferred income tax liabilities, non-current (included in income taxes payable)	Represents the noncurrent portion of deferred tax liabilities, which result from applying the applicable tax rate to net taxable temporary differences pertaining to each jurisdiction to which the entity is obligated to pay income tax. A noncurrent taxable temporary difference is a difference between the tax basis and the carrying amount of a noncurrent asset or liability in the financial statements prepared in accordance with generally accepted accounting principles. In a classified statement of financial position, an enterprise shall separate deferred tax liabilities and assets into a current amount and a noncurrent amount. Deferred tax liabilities and assets shall be classified as current or noncurrent based on the classification of the related asset or liability for financial reporting. A deferred tax liability or asset that is not related to an asset or liability for financial reporting, including deferred tax assets related to carryforwards, shall be classified according to the expected reversal date of the temporary difference.	Bristol-Myers Squibb Co.'s deferred income tax liabilities, non-current (included in income taxes payable) increased from 2015 to 2016 but then slightly declined from 2016 to 2017.

Top

Analyst Adjustments: Removal of Deferred Taxes

Bristol-Myers Squibb Co., adjustments to financial data

USD $ in millions

	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015	Dec 31, 2014	Dec 31, 2013
Adjustment to Current Assets
Current assets (as reported)	14,854	13,704	10,415	14,608	18,916
Less: Current deferred tax assets, net	–	–	–	1,644	1,826
Current assets (adjusted)	14,854	13,704	10,415	12,964	17,090
Adjustment to Total Assets
Total assets (as reported)	33,551	33,707	31,748	33,749	38,592
Less: Current deferred tax assets, net	–	–	–	1,644	1,826
Less: Noncurrent deferred tax assets, net	1,610	2,996	2,844	915	508
Total assets (adjusted)	31,941	30,711	28,904	31,190	36,258
Adjustment to Current Liabilities
Current liabilities (as reported)	9,563	8,841	8,017	8,461	12,440
Less: Current deferred tax liabilities, net	–	–	–	11	956
Current liabilities (adjusted)	9,563	8,841	8,017	8,450	11,484
Adjustment to Total Liabilities
Total liabilities (as reported)	21,704	17,360	17,324	18,766	23,356
Less: Current deferred tax liabilities, net	–	–	–	11	956
Less: Noncurrent deferred tax liabilities, net	45	47	31	60	73
Total liabilities (adjusted)	21,659	17,313	17,293	18,695	22,327
Adjustment to Total Bristol-Myers Squibb Company Shareholders' Equity
Total Bristol-Myers Squibb Company shareholders' equity (as reported)	11,741	16,177	14,266	14,852	15,154
Less: Net deferred tax assets (liabilities)	1,565	2,949	2,813	2,488	1,305
Total Bristol-Myers Squibb Company shareholders' equity (adjusted)	10,176	13,228	11,453	12,364	13,849
Adjustment to Net Earnings Attributable To BMS
Net earnings attributable to BMS (as reported)	1,007	4,457	1,565	2,004	2,563
Add: Deferred income tax expense (benefit)	1,010	(204)	(347)	(542)	(491)
Net earnings attributable to BMS (adjusted)	2,017	4,253	1,218	1,462	2,072

Top

Adjusted Ratios: Removal of Deferred Taxes (Summary)

Bristol-Myers Squibb Co., adjusted ratios

	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015	Dec 31, 2014	Dec 31, 2013
Current Ratio
Reported current ratio	1.55	1.55	1.30	1.73	1.52
Adjusted current ratio	1.55	1.55	1.30	1.53	1.49
Net Profit Margin
Reported net profit margin	4.85%	22.94%	9.45%	12.62%	15.64%
Adjusted net profit margin	9.71%	21.89%	7.36%	9.21%	12.65%
Total Asset Turnover
Reported total asset turnover	0.62	0.58	0.52	0.47	0.42
Adjusted total asset turnover	0.65	0.63	0.57	0.51	0.45
Financial Leverage
Reported financial leverage	2.86	2.08	2.23	2.27	2.55
Adjusted financial leverage	3.14	2.32	2.52	2.52	2.62
Return on Equity (ROE)
Reported ROE	8.58%	27.55%	10.97%	13.49%	16.91%
Adjusted ROE	19.82%	32.15%	10.63%	11.82%	14.96%
Return on Assets (ROA)
Reported ROA	3.00%	13.22%	4.93%	5.94%	6.64%
Adjusted ROA	6.31%	13.85%	4.21%	4.69%	5.71%

Ratio	Description	The company
Adjusted current ratio	A liquidity ratio calculated as adjusted current assets divided by adjusted current liabilities.	Bristol-Myers Squibb Co.'s adjusted current ratio improved from 2015 to 2016 and from 2016 to 2017.
Adjusted net profit margin	An indicator of profitability, calculated as adjusted net income divided by total revenue.	Bristol-Myers Squibb Co.'s adjusted net profit margin improved from 2015 to 2016 but then slightly deteriorated from 2016 to 2017 not reaching 2015 level.
Adjusted total asset turnover	An activity ratio calculated as total revenue divided by adjusted total assets.	Bristol-Myers Squibb Co.'s adjusted total asset turnover improved from 2015 to 2016 and from 2016 to 2017.
Adjusted financial leverage	A measure of financial leverage calculated as adjusted total assets divided by adjusted total equity. Financial leverage is the extent to which a company can effect, through the use of debt, a proportional change in the return on common equity that is greater than a given proportional change in operating income.	Bristol-Myers Squibb Co.'s adjusted financial leverage declined from 2015 to 2016 but then increased from 2016 to 2017 exceeding 2015 level.
Adjusted ROE	A profitability ratio calculated as adjusted net income divided by adjusted shareholders' equity.	Bristol-Myers Squibb Co.'s adjusted ROE improved from 2015 to 2016 but then slightly deteriorated from 2016 to 2017 not reaching 2015 level.
Adjusted ROA	A profitability ratio calculated as adjusted net income divided by adjusted total assets.	Bristol-Myers Squibb Co.'s adjusted ROA improved from 2015 to 2016 but then slightly deteriorated from 2016 to 2017 not reaching 2015 level.

Top

Adjusted Current Ratio

	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015	Dec 31, 2014	Dec 31, 2013
As Reported
Current assets (USD $ in millions)	14,854	13,704	10,415	14,608	18,916
Current liabilities (USD $ in millions)	9,563	8,841	8,017	8,461	12,440

Current ratio¹	1.55	1.55	1.30	1.73	1.52
Adjusted for Deferred Taxes
Adjusted current assets (USD $ in millions)	14,854	13,704	10,415	12,964	17,090
Adjusted current liabilities (USD $ in millions)	9,563	8,841	8,017	8,450	11,484

Adjusted current ratio²	1.55	1.55	1.30	1.53	1.49

2017 Calculations

¹ Current ratio = Current assets ÷ Current liabilities
= 14,854 ÷ 9,563 = 1.55

² Adjusted current ratio = Adjusted current assets ÷ Adjusted current liabilities
= 14,854 ÷ 9,563 = 1.55

Ratio	Description	The company
Adjusted current ratio	A liquidity ratio calculated as adjusted current assets divided by adjusted current liabilities.	Bristol-Myers Squibb Co.'s adjusted current ratio improved from 2015 to 2016 and from 2016 to 2017.

Top

Adjusted Net Profit Margin

	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015	Dec 31, 2014	Dec 31, 2013
As Reported
Net earnings attributable to BMS (USD $ in millions)	1,007	4,457	1,565	2,004	2,563
Revenues (USD $ in millions)	20,776	19,427	16,560	15,879	16,385

Net profit margin¹	4.85%	22.94%	9.45%	12.62%	15.64%
Adjusted for Deferred Taxes
Adjusted net earnings attributable to BMS (USD $ in millions)	2,017	4,253	1,218	1,462	2,072

Adjusted net profit margin²	9.71%	21.89%	7.36%	9.21%	12.65%

2017 Calculations

¹ Net profit margin = 100 × Net earnings attributable to BMS ÷ Revenues
= 100 × 1,007 ÷ 20,776 = 4.85%

² Adjusted net profit margin = 100 × Adjusted net earnings attributable to BMS ÷ Revenues
= 100 × 2,017 ÷ 20,776 = 9.71%

Ratio	Description	The company
Adjusted net profit margin	An indicator of profitability, calculated as adjusted net income divided by total revenue.	Bristol-Myers Squibb Co.'s adjusted net profit margin improved from 2015 to 2016 but then slightly deteriorated from 2016 to 2017 not reaching 2015 level.

Top

Adjusted Total Asset Turnover

	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015	Dec 31, 2014	Dec 31, 2013
As Reported
Revenues (USD $ in millions)	20,776	19,427	16,560	15,879	16,385
Total assets (USD $ in millions)	33,551	33,707	31,748	33,749	38,592

Total asset turnover¹	0.62	0.58	0.52	0.47	0.42
Adjusted for Deferred Taxes
Adjusted total assets (USD $ in millions)	31,941	30,711	28,904	31,190	36,258

Adjusted total asset turnover²	0.65	0.63	0.57	0.51	0.45

2017 Calculations

¹ Total asset turnover = Revenues ÷ Total assets
= 20,776 ÷ 33,551 = 0.62

² Adjusted total asset turnover = Revenues ÷ Adjusted total assets
= 20,776 ÷ 31,941 = 0.65

Ratio	Description	The company
Adjusted total asset turnover	An activity ratio calculated as total revenue divided by adjusted total assets.	Bristol-Myers Squibb Co.'s adjusted total asset turnover improved from 2015 to 2016 and from 2016 to 2017.

Top

Adjusted Financial Leverage

	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015	Dec 31, 2014	Dec 31, 2013
As Reported
Total assets (USD $ in millions)	33,551	33,707	31,748	33,749	38,592
Total Bristol-Myers Squibb Company shareholders' equity (USD $ in millions)	11,741	16,177	14,266	14,852	15,154

Financial leverage¹	2.86	2.08	2.23	2.27	2.55
Adjusted for Deferred Taxes
Adjusted total assets (USD $ in millions)	31,941	30,711	28,904	31,190	36,258
Adjusted total Bristol-Myers Squibb Company shareholders' equity (USD $ in millions)	10,176	13,228	11,453	12,364	13,849

Adjusted financial leverage²	3.14	2.32	2.52	2.52	2.62

2017 Calculations

¹ Financial leverage = Total assets ÷ Total Bristol-Myers Squibb Company shareholders' equity
= 33,551 ÷ 11,741 = 2.86

² Adjusted financial leverage = Adjusted total assets ÷ Adjusted total Bristol-Myers Squibb Company shareholders' equity
= 31,941 ÷ 10,176 = 3.14

Ratio	Description	The company
Adjusted financial leverage	A measure of financial leverage calculated as adjusted total assets divided by adjusted total equity. Financial leverage is the extent to which a company can effect, through the use of debt, a proportional change in the return on common equity that is greater than a given proportional change in operating income.	Bristol-Myers Squibb Co.'s adjusted financial leverage declined from 2015 to 2016 but then increased from 2016 to 2017 exceeding 2015 level.

Top

Adjusted Return on Equity (ROE)

	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015	Dec 31, 2014	Dec 31, 2013
As Reported
Net earnings attributable to BMS (USD $ in millions)	1,007	4,457	1,565	2,004	2,563
Total Bristol-Myers Squibb Company shareholders' equity (USD $ in millions)	11,741	16,177	14,266	14,852	15,154

ROE¹	8.58%	27.55%	10.97%	13.49%	16.91%
Adjusted for Deferred Taxes
Adjusted net earnings attributable to BMS (USD $ in millions)	2,017	4,253	1,218	1,462	2,072
Adjusted total Bristol-Myers Squibb Company shareholders' equity (USD $ in millions)	10,176	13,228	11,453	12,364	13,849

Adjusted ROE²	19.82%	32.15%	10.63%	11.82%	14.96%

2017 Calculations

¹ ROE = 100 × Net earnings attributable to BMS ÷ Total Bristol-Myers Squibb Company shareholders' equity
= 100 × 1,007 ÷ 11,741 = 8.58%

² Adjusted ROE = 100 × Adjusted net earnings attributable to BMS ÷ Adjusted total Bristol-Myers Squibb Company shareholders' equity
= 100 × 2,017 ÷ 10,176 = 19.82%

Ratio	Description	The company
Adjusted ROE	A profitability ratio calculated as adjusted net income divided by adjusted shareholders' equity.	Bristol-Myers Squibb Co.'s adjusted ROE improved from 2015 to 2016 but then slightly deteriorated from 2016 to 2017 not reaching 2015 level.

Top

Adjusted Return on Assets (ROA)

	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015	Dec 31, 2014	Dec 31, 2013
As Reported
Net earnings attributable to BMS (USD $ in millions)	1,007	4,457	1,565	2,004	2,563
Total assets (USD $ in millions)	33,551	33,707	31,748	33,749	38,592

ROA¹	3.00%	13.22%	4.93%	5.94%	6.64%
Adjusted for Deferred Taxes
Adjusted net earnings attributable to BMS (USD $ in millions)	2,017	4,253	1,218	1,462	2,072
Adjusted total assets (USD $ in millions)	31,941	30,711	28,904	31,190	36,258

Adjusted ROA²	6.31%	13.85%	4.21%	4.69%	5.71%

2017 Calculations

¹ ROA = 100 × Net earnings attributable to BMS ÷ Total assets
= 100 × 1,007 ÷ 33,551 = 3.00%

² Adjusted ROA = 100 × Adjusted net earnings attributable to BMS ÷ Adjusted total assets
= 100 × 2,017 ÷ 31,941 = 6.31%

Ratio	Description	The company
Adjusted ROA	A profitability ratio calculated as adjusted net income divided by adjusted total assets.	Bristol-Myers Squibb Co.'s adjusted ROA improved from 2015 to 2016 but then slightly deteriorated from 2016 to 2017 not reaching 2015 level.

Top